Evidence of acetylcholinesterase inhibitors in treating Alzheimer's disease in very old patients is uncertain [9]

Journal of the American Geriatrics Society

Volumn 53, Issue 9, 2005, Pages 1640-

  Cheng, Huai Yong ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; GENOTYPE; HUMAN; INCIDENCE; LETTER; MEDICAL CARE; NEUROPATHOLOGY; PREVALENCE; TREATMENT OUTCOME; AGED; METHODOLOGY; NOTE;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; INDANS; PIPERIDINES; RESEARCH DESIGN;

EID: 27744505872     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.53487_9.x     Document Type: Letter

References (7)

1. Royall DR. The emperor has no clothes. Dementia treatment on the eve of the aging era. J Am Geriatr Soc 2005;53:163-164.
2. Schoenmaker N, Van Gool WA. The age gap between patients in clinical studies and in the general population: A pitfall for dementia research. Lancet Neurol 2004;3:627-630.
3. Whitehead A, Perdomo C, Pratt RD et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: A meta-analysis of individual patient data from randomized controlled trials. Int J Geriatr Psychiatry 2004;19:624-633.
4. Courtney C, Farrell D, Gray R et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD 2000): Randomized double-blind trial. Lancet 2004;363:2105-2115.
5. Gray R, Bentham P, Hills R. Authors' reply. Lancet 2004;364:1216.
6. Tonelli MR. The limits of evidence-based medicine, Respir Care 2001;46: 1435-1440.
7. Hogan DB, Goldlist B, Naglie G et al. Comparison studies of cholinesterase inhibitors for Alzheimer's disease. Lancet Neurol 2004;3:622-626.